Displaying 111 - 120 of 1290 Results
News Public Client

West Virginia negotiates more than $260 million in preliminary settlements with opioid manufacturers Allergan, J&J, Teva, ending trial

May 26, 2022 | by: Motley Rice
West Virginia, with the support of Motley Rice as outside counsel, has reached a $161.5 million preliminary settlement with opioid manufacturers Allergan and Teva.
News Public Client

Washington state secures more than $500 million in settlement with nation's "Big Three" opioid distributors

May 5, 2022 | by: Motley Rice
The State of Washington, represented by outside trial counsel Motley Rice LLC, reached a preliminary settlement worth more than $500 million on May 3, 2022, roughly five months into what was one of the first state cases to go to trial against AmerisourceBergen, Cardinal Health and McKesson.
News Securities Class Actions | Antitrust

Serena Hallowell, Michelle Clerkin named to Law360 Editorial Advisory Boards

May 5, 2022 | by: Motley Rice
Legal publication Law360 selected two Motley Rice attorneys to sit on its Editorial Advisory Boards for the 2022 term. Veteran litigator Serena Hallowell is one of 11 attorneys who will advise on Law360’s coverage of securities fraud litigation, and antitrust attorney Michelle Clerkin is one of 14 attorneys who will…
News Securities Class Actions

Benchmark Litigation names Motley Rice Plaintiff Firm of the Year

April 13, 2022 | by: Motley Rice
Benchmark Litigation U.S. Awards recognized Motley Rice in four categories, including 2022 Plaintiff Firm of the Year, citing the firm’s lead role in negotiating an $809.5 million settlement for Twitter shareholders.
News Anti-Terrorism Lawsuit

Declassified FBI documents link senior Saudi official to suspected spy who helped September 11, 2001 hijackers

March 30, 2022 | by: Motley Rice
The FBI declassified a 2017 report this month that links a senior Saudi official to a suspected spy with known ties to at least two of the Sept. 11, 2001 hijackers.
News Public Client

Rhode Island reaches $107 million settlement with opioid manufacturers Teva and Allergan at trial opening

March 23, 2022 | by: Motley Rice
As outside counsel to The State of Rhode Island, Motley Rice attorneys were by the side of Attorney General Peter Neronha as he finalized a preliminary settlement with opioid manufacturers Allergan and Teva Pharmaceutical Industries on March 21, 2022.
News Public Client

"Big Three" opioid distributors, J&J advance $26 billion settlements

February 24, 2022 | by: Motley Rice
After a month-long review of nationwide participation, opioid manufacturer Johnson & Johnson and the U.S.’s three largest opioid distributors- AmerisourceBergen, Cardinal Health and McKesson- agreed today to move forward with combined $26 billion settlements.
Blog Public Client

Significant opioid relief finally on the way | Causes, Not Just Cases®

February 24, 2022 | by: Joseph F. Rice
Today’s announcement that the biggest three opioid distributors AmerisourceBergen, Cardinal Health, McKesson and manufacturer Johnson & Johnson will move forward and finalize $26 billion in opioid funding comes as welcome news for the millions of families, first responders and others nationwide who know all too…
News Securities Class Actions | Medical Device Lawsuits

Law360 names Motley Rice a 2021 Product Liability Practice Group of the Year

February 18, 2022 | by: Motley Rice
Legal publication Law360 recognized Motley Rice as a 2021 Practice Group of the Year in the Product Liability. Only five firms nationwide received the award.
Blog Toxic Exposure | Women’s Health Lawsuits

Studies show cow-milk baby formula products can cause deadly intestinal disease in premature babies | Causes, Not Just Cases®

February 17, 2022 | by: Laura K. Stemkowski
Necrotizing enterocolitis (NEC) is a gastrointestinal disease that affects the most vulnerable among us – premature infants. It is a serious, sometimes fatal condition with potentially lifelong consequences. While NEC is a known risk for preterm infants, researchers have found that a seemingly innocent sources can…